{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:34:53Z","timestamp":1794573293196,"version":"4.9.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000374","name":"British Medical Association","doi-asserted-by":"publisher","award":["NIHR303144"],"award-info":[{"award-number":["NIHR303144"]}],"id":[{"id":"10.13039\/501100000374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007568","name":"Urology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016338","name":"Imperial Experimental Cancer Medicine Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.eururo.2025.05.038","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:42:11Z","timestamp":1749771731000},"page":"247-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Magnetic Resonance Imaging\u2013based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review"],"prefix":"10.1016","volume":"88","author":[{"given":"Ivo G.","family":"Schoots","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Asbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka A.","family":"Godtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonit","family":"Punwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wallstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar R.","family":"Padhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.05.038_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.05.038_b0010","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","article-title":"Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021","volume":"80","author":"Van Poppel","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.038_b0015","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.05.038_b0020","unstructured":"European Council. Council updates its recommendation to screen for cancer. Council of the European Union December 9, 2022."},{"key":"10.1016\/j.eururo.2025.05.038_b0025","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/s41598-021-81459-2","article-title":"The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study","volume":"11","author":"Getaneh","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2025.05.038_b0030","unstructured":"SAPEA. Improving cancer screening in the European Union. Evidence Review Report No10. Science Advice for Policy by European Academies; 2022."},{"key":"10.1016\/j.eururo.2025.05.038_b0035","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1007\/s00330-024-10626-6","article-title":"Key learning on the promise and limitations of MRI in prostate cancer screening","volume":"34","author":"Padhani","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2025.05.038_b0040","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","article-title":"Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis","volume":"10","author":"Fazekas","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.05.038_b0045","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2025.05.038_b0050","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2025.05.038_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059482","article-title":"Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial","volume":"12","author":"Nam","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.eururo.2025.05.038_b0060","article-title":"Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study","volume":"2","author":"Moore","year":"2023","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.eururo.2025.05.038_b0065","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2020.7456","article-title":"Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study","volume":"7","author":"Eldred-Evans","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.05.038_b0070","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.euf.2024.02.006","article-title":"Opportunistic prostate cancer screening with biparametric magnetic resonance imaging (VISIONING)","volume":"10","author":"Wetterauer","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.05.038_b0075","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s00330-023-10019-1","article-title":"Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial\u2014Prostate Cancer Secondary Screening in Sapienza (PROSA)","volume":"34","author":"Messina","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2025.05.038_b0080","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.038_b0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.038_b0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.eururo.2023.09.027","article-title":"Multiparametric magnetic resonance imaging in prostate cancer screening at the age of 45 years: results from the first screening round of the PROBASE trial","volume":"85","author":"Boschheidgen","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.038_b0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eururo.2023.11.013","article-title":"Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men","volume":"85","author":"Bratt","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.038_b0100","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","article-title":"Imaging-based prostate cancer screening among BRCA mutation carriers\u2014results from the first round of screening","volume":"31","author":"Segal","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.05.038_b0105","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/bju.15535","article-title":"The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening","volume":"129","author":"Benafif","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.05.038_b0110","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/UPJ.0000000000000435","article-title":"An examination of racial and ethnic disparities in the use of prostate biopsy and magnetic resonance imaging in prostate cancer screening","volume":"10","author":"Chartrand","year":"2023","journal-title":"Urol Pract"},{"key":"10.1016\/j.eururo.2025.05.038_b0115","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1002\/bco2.424","article-title":"Impact of prostate cancer screening in European ancestry un-affected men with germline DNA repair pathogenic variants","volume":"6","author":"Fasulo","year":"2025","journal-title":"BJUI Compass"},{"key":"10.1016\/j.eururo.2025.05.038_b0120","doi-asserted-by":"crossref","unstructured":"Stroomberg HV, Brasso K, Blak AA, Byrjalsen A, Hansen TVO, Roder A. Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1\/2 variants. Prostate Cancer Prostatic Dis. In press. https:\/\/doi.org\/10.1038\/s41391-025-00938-z.","DOI":"10.1038\/s41391-025-00938-z"},{"key":"10.1016\/j.eururo.2025.05.038_b0125","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results after four years of screening for prostate cancer with PSA and MRI","volume":"391","author":"Hugosson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.05.038_b0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54577","article-title":"Repeated prostate cancer screening using prostate-specific antigen testing and magnetic resonance imaging: a secondary analysis of the STHLM3-MRI randomized clinical trial","volume":"7","author":"Nordstrom","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2025.05.038_b0135","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2017.06.019","volume":"73","author":"Alberts","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.038_b0140","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eururo.2015.12.006","article-title":"Role of magnetic resonance imaging in prostate cancer screening: a pilot study within the Goteborg Randomised Screening Trial","volume":"70","author":"Grenabo Bergdahl","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.038_b0145","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euo.2021.09.001","article-title":"Prostate cancer screening with magnetic resonance imaging: results from the second round of the Goteborg Prostate Cancer Screening 2 Trial","volume":"5","author":"Wallstrom","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.05.038_b0150","doi-asserted-by":"crossref","unstructured":"Discacciati A, Abbadi A, Clements MS, et al. Repeat prostate cancer screening using blood-based risk prediction or prostate-specific antigen in the era of magnetic resonance imaging-guided biopsies: a secondary analysis of the STHLM3-MRI randomized clinical trial. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.10.016.","DOI":"10.1016\/j.euo.2024.10.016"},{"key":"10.1016\/j.eururo.2025.05.038_b0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2024.01.017","article-title":"Prostate cancers in the prostate-specific antigen interval of 1.8\u20133 ng\/ml: results from the G\u00f6teborg-2 Prostate Cancer Screening Trial","volume":"86","author":"M\u00f6ller","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.038_b0160","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bju.15683","article-title":"Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study","volume":"130","author":"Rannikko","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.05.038_b0165","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstrom","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.05.038_b0170","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.05.038_b0175","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4103\/aja20239","article-title":"The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men","volume":"25","author":"Chiu","year":"2023","journal-title":"Asian J Androl"},{"key":"10.1016\/j.eururo.2025.05.038_b0180","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.7131","article-title":"Biomarker vs MRI-enhanced strategies for prostate cancer screening: the STHLM3-MRI randomized clinical trial","volume":"7","author":"Bjornebo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2025.05.038_b0185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2024.04.037","article-title":"Performance of 4Kscore as a reflex test to prostate-specific antigen in the GOTEBORG-2 Prostate Cancer Screening Trial","volume":"86","author":"Josefsson","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.038_b0190","doi-asserted-by":"crossref","unstructured":"Schoots IG, Haider MA, Punwani S, Padhani AR. MRI in prostate cancer screening: a review and recommendations, from the AJR special series on screening. AJR Am J Roentgenol. In press. https:\/\/doi.org\/10.2214\/AJR.24.32588.","DOI":"10.2214\/AJR.24.32588"},{"key":"10.1016\/j.eururo.2025.05.038_b0195","doi-asserted-by":"crossref","first-page":"871","DOI":"10.7326\/M23-1504","article-title":"Lifetime health and economic outcomes of biparametric magnetic resonance imaging as first-line screening for prostate cancer: a decision model analysis","volume":"177","author":"Gulati","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2025.05.038_b0200","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.038_b0205","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.038_b0210","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","article-title":"Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer","volume":"9","author":"Darst","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.05.038_b0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.1594","article-title":"A paradigm shift toward population-based MRI-targeted prostate cancer screening","author":"Schoots","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.05.038_b0220","unstructured":"Prostate Cancer UK. TRANSFORM trial. 2024. https:\/\/prostatecanceruk.org\/research\/transform-trial."},{"key":"10.1016\/j.eururo.2025.05.038_b0225","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/ijc.33940","article-title":"A randomized trial of risk-adapted screening for prostate cancer in young men\u2014results of the first screening round of the PROBASE trial","volume":"150","author":"Arsov","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2025.05.038_b0230","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw165","article-title":"Repeat prostate-specific antigen tests before prostate biopsy decisions","volume":"108","author":"Nordstr\u00f6m","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2025.05.038_b0235","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2024.09.003","article-title":"Risk-stratified approach to implementing population-based prostate cancer screening in five pilot sites in the European Union: a protocol for the PRAISE-U project","volume":"70","author":"Chandran","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.05.038_b0240","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.05.038_b0245","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","article-title":"Prostate Imaging Reporting and Data System 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Maggi","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.05.038_b0250","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bju.15899","article-title":"The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway","volume":"131","author":"Eldred-Evans","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.05.038_b0255","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2214\/AJR.20.24268","article-title":"PI-RADS Committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review","volume":"216","author":"Schoots","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.eururo.2025.05.038_b0260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.05.038_b0265","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/bjr\/tqad027","article-title":"Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making","volume":"97","author":"Rajendran","year":"2024","journal-title":"Br J Radiol"},{"key":"10.1016\/j.eururo.2025.05.038_b0270","unstructured":"Interactive report from SweOPT (Interaktiv rapport fr\u00e5n SweOPT). 2025. https:\/\/statistik.incanet.se\/opt\/."},{"key":"10.1016\/j.eururo.2025.05.038_b0275","doi-asserted-by":"crossref","first-page":"103191","DOI":"10.1016\/j.eclinm.2025.103191","article-title":"Evaluating the performance of existing tools to predict clinically significant prostate cancer in men with indeterminate lesions on biparametric MRI and development of a novel multiplex model: a prospective cohort study","volume":"82","author":"Abbadi","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.eururo.2025.05.038_b0280","series-title":"Combined MRI targeted and systematic biopsy in young men (45\u201354 years) with suspicious PSA in a prostate cancer screening setting\u2014data from the PROBASE trial","author":"Al-Monajjed","year":"2025"},{"key":"10.1016\/j.eururo.2025.05.038_b0285","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.euo.2024.10.006","article-title":"Regional versus systematic biopsy in addition to targeted biopsy: results from a systematic review and meta-analysis","volume":"8","author":"Sanguedolce","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.05.038_b0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002063","article-title":"Improving clinical risk stratification at diagnosis in primary prostate cancer: a prognostic modelling study","volume":"13","author":"Gnanapragasam","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2025.05.038_b0295","unstructured":"Cornford P, Tilki D, van den Bergh, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer 2024. 2024."},{"key":"10.1016\/j.eururo.2025.05.038_b0300","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2025.05.038_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103022","article-title":"Monitoring of prostate cancer screening in the European Union: development of key performance indicators through the PRAISE-U project","volume":"80","author":"Singh","year":"2025","journal-title":"eClinicalMedicine"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825003410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825003410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T20:30:45Z","timestamp":1762288245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825003410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0302283825003410"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.05.038","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Magnetic Resonance Imaging\u2013based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}